FIG 2.
Overall survival according to the presence of ALK resistance mutations or other mutations in the liquid biopsy in ALK positive population. (A) PD while receiving TKI therapy, by ALK status. (B) PD while receiving TKI therapy, by ALK type. PD, disease progression; TKI, tyrosine kinase inhibitor.